# case_05_node_1

## Outcome

- Run status: complete; final source: LLM.
- Target: gamma knife/SRS plus continued furmonertinib after isolated CNS progression.
- Retrieval found one useful strategy-level analog: EGFR-mutant NSCLC treated with osimertinib plus SRS, followed by partial response. It also found ROS1/MET/local-therapy analogs with major limitations.

## Component audit

- Evidence Review accepted six analogs and four counters. One accepted analog was entity `different`; four analogs had relevance below 0.35.
- Several `counter` items did not contradict the target strategy; they merely described different salvage treatments or populations. “Off-target/irrelevant” was confused with counter-evidence.
- AnswerMemory atomicity held: ten claims remained separate.
- Context preserved limitations, but retained six analog findings instead of selecting the single closest analogy.
- Generate cited all six retained analogs. The osimertinib+SRS case was useful, while MET/ROS1 cases without outcomes and afatinib irradiation at a non-brain site added citation volume without comparable information gain.

## Classification

- Repeated general issue: analog admission is too broad.
- Repeated general issue: the pipeline lacks an analog hierarchy and a final “best analog only” selection step.
- Role taxonomy issue: `counter` must mean a comparable result in the opposite direction, not simply a different intervention/population.
- Skill candidate: grade clinical analogs by strategy, drug class, molecular driver, progression pattern, anatomical site, outcome and time window; retain only the nearest non-redundant analogs.
